| abstract |
A novel therapeutic agent for lymphedema is provided. A β2 stimulant or a pharmacologically acceptable salt thereof. The β2 stimulant is selected from the group consisting of fenoterol, clenbuterol, terbutaline, salmeterol, tulobuterol, formoterol, isoproterenol, salbutamol, levosalbutamol, pyrbuterol, procaterol, metaproterenol, vitorterol, birantelol, bambuterol and indacaterol The Fenoterol, a β2 stimulator, activated the Akt / eNOS signaling pathway and proliferated lymphatic endothelial cells. [Selection figure] None |